PLUS THERAPEUTICS, INC.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
CNSY$0.57-11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and par value data)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $3,022 | $4,256 |
| Restricted cash and cash equivalents | — | 4,502 |
| Investments | 12,092 | 4,356 |
| Grant receivable | 1,350 | 322 |
| Other current assets | 1,564 | 1,734 |
| Total current assets | 18,028 | 15,170 |
| Property and equipment, net | 1,013 | 257 |
| Operating lease right-of-use assets | 57 | 70 |
| Goodwill | 372 | 372 |
| Intangible assets, net | 299 | 333 |
| Other assets | 147 | 123 |
| Total assets | $19,916 | $16,325 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $6,157 | $5,920 |
| Investor liability pursuant to Letter Agreement | — | 4,502 |
| Operating lease liability | 58 | 56 |
| Deferred grant liability | 927 | 927 |
| Line of credit | 667 | 750 |
| Other liabilities | 146 | 159 |
| Total current liabilities | 7,955 | 12,314 |
| Noncurrent operating lease liability | — | 15 |
| Total liabilities | 7,955 | 12,329 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.001 par value; 2,000,000,000 shares authorized; 6,872,364 and 5,557,371 shares issued as of March 31, 2026 and December 31, 2025, respectively; 6,862,027 and 5,547,034 shares outstanding as of March 31, 2026 and December 31, 2025, respectively | 7 | 6 |
| Treasury stock (at cost), 10,337 shares as of March 31, 2026 and December 31, 2025, respectively | (500) | (500) |
| Additional paid-in capital | 535,265 | 520,355 |
| Accumulated deficit | (522,811) | (515,865) |
| Total stockholders’ equity | 11,961 | 3,996 |
| Total liabilities and stockholders’ equity | $19,916 | $16,325 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.